Chen Holly Yu, Welby Emily, Li Tiansen, Swaroop Anand
Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Transl Sci Rare Dis. 2019 Jul 4;4(1-2):97-115. doi: 10.3233/TRD-190038.
Ciliopathies display extensive genetic and clinical heterogeneity, varying in severity, age of onset, disease progression and organ systems affected. Retinal involvement, as demonstrated by photoreceptor dysfunction or death, is a highly penetrant phenotype among a vast majority of ciliopathies. Photoreceptor cells possess a specialized and modified sensory cilium with membrane discs where efficient photon capture and ensuing signaling cascade initiate the visual process. Disruptions of cilia biogenesis and protein transport lead to impairment of photoreceptor function and eventually degeneration. Despite advances in elucidation of ciliogenesis and photoreceptor cilia defects, we have limited understanding of pathogenic mechanisms underlying retinal phenotype(s) observed in human ciliopathies. Patient-derived induced pluripotent stem cell (iPSC)-based approaches offer a unique opportunity to complement studies with model organisms and examine cilia disease relevant to humans. Three-dimensional retinal organoids from iPSC lines feature laminated cytoarchitecture, apical-basal polarity and emergence of a ciliary structure, thereby permitting pathogenic modeling of human photoreceptors . Here, we review the biology of photoreceptor cilia and associated defects and discuss recent progress in evolving treatment modalities, especially using patient-derived iPSCs, for retinal ciliopathies.
纤毛病表现出广泛的遗传和临床异质性,在严重程度、发病年龄、疾病进展和受影响的器官系统方面存在差异。如光感受器功能障碍或死亡所表明的那样,视网膜受累是绝大多数纤毛病中一种高度外显的表型。光感受器细胞拥有一个特殊的、经过修饰的感觉纤毛,其带有膜盘,在那里高效的光子捕获和随后的信号级联反应启动视觉过程。纤毛生物发生和蛋白质运输的破坏会导致光感受器功能受损并最终退化。尽管在阐明纤毛发生和光感受器纤毛缺陷方面取得了进展,但我们对人类纤毛病中观察到的视网膜表型的致病机制了解有限。基于患者来源的诱导多能干细胞(iPSC)的方法为补充模式生物研究和研究与人类相关的纤毛病提供了独特的机会。来自iPSC系的三维视网膜类器官具有分层的细胞结构、顶-基极性和纤毛结构的出现,从而允许对人类光感受器进行致病建模。在这里,我们综述了光感受器纤毛的生物学和相关缺陷,并讨论了在不断发展的治疗方式方面的最新进展,特别是使用患者来源的iPSC治疗视网膜纤毛病。